Published in Pain and Central Nervous System Week, July 7th, 2008
Under a 2007 agreement between the two companies, Micromet and Nycomed develop MT203, a fully human anti-GM-CSF antibody that may be useful for the treatment of various inflammatory and autoimmune diseases. Preclinical studies support MT203's development for the treatment of rheumatoid arthritis and several other indications, including multiple sclerosis, psoriasis, asthma and chronic obstructive pulmonary disease.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week